Abstract
BACKGROUND: The ANGPT (angiopoietin)-TEK (tyrosine kinase, endothelial) vascular signaling pathway plays a key role in the formation of Schlemm canal, and loss-of-function mutations in the TEK or ANGPT1 gene are associated with primary congenital glaucoma in children. In genome-wide association studies, an association was identified between protection from primary open-angle glaucoma and the single-nucleotide polymorphism rs76020419 (G>T), located within a predicted miR-145-binding site in the 3′ untranslated region of ANGPT2. To date, the functional impact of this variant in the anterior chamber of the eye remains largely unexplored. METHODS: MT (mutant) mice harboring an orthologous rs76020419 minor allele (T) were generated using CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat-associated 9). Plasma and tissue samples, including eyes, were collected, and ANGPT2 expression was quantified using ELISA. Anterior segments from eyes were collected from WT (wild-type) and MT mice, and Schlemm canal area was quantified. RESULTS: In the MT group, higher ANGPT2 concentrations were observed in the plasma, lungs, kidneys, and eyes (P=0.0212, P<0.001, P=0.0815, and P=0.0215, respectively). Additionally, the Schlemm canal was larger in MT mice compared with WT mice (P=0.0430). CONCLUSIONS: The rs76020419 minor allele (T) is associated with increased levels of ANGPT2 and a larger Schlemm canal in mice. These findings suggest a potential protective mechanism in glaucoma.
Original language | English (US) |
---|---|
Pages (from-to) | 2207-2212 |
Number of pages | 6 |
Journal | Arteriosclerosis, thrombosis, and vascular biology |
Volume | 44 |
Issue number | 10 |
DOIs | |
State | Published - Oct 1 2024 |
Funding
This work was supported by the National Institutes of Health (NIH) R01EY025799-05 and NIH P30DK114857 to S.E. Quaggin, NIH R01 EY032609, a Bright Focus Foundation New Investigator fellowship, the Northwestern University Transgenic and Targeted Mutagenesis Laboratory, the Center for Advanced Microscopy of the Feinberg School of Medicine , and a Cancer Center Support Grant (NCI CCSGP30 CA060553). S.E. Quaggin is listed as an inventor in patents related to the therapeutic targeting of the ANGPT (angiopoietin)-TEK (tyrosine kinase, endothelial) pathway in ocular hypertension and glaucoma and is a founder and owns stock in Mannin Research. Additionally, S.E. Quaggin receives consulting fees from AstraZeneca and Roche/Genentech and is a member of the board of directors of AbbVie. B.R. Thomson has applied for a patent related to the therapeutic targeting of the ANGPT-TEK pathway. Unrelated to this research, B.R. Thomson has received research funding from Bayer. The other authors report no conflicts.
Keywords
- angiopoietins
- glaucoma
- kidney
- microRNAs
- Schlemm canal
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine